OPRD1
Delta-type opioid receptor
As of the edition of 20 October 2026, OPRD1 (delta-type opioid receptor, UniProt P41143) has 14 drugs tested at it and 34 companies on the list, 6 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41143
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 18
- Disease areas
- Mental health; Chemically induced; Nervous system; Nutrition and metabolism; Bones, joints and muscles; Immune system; Skin and connective tissue; Cancer
- Registered trials of its drugs
- 713
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 5 |
| Stopped | 2 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Naltrexone | Marketed | Phase 4 | none listed |
| Naloxone | Marketed | Phase 4 | none listed |
| Hydrocodone | Marketed | Phase 4 | none listed |
| Nalbuphine | Marketed | Phase 4 | none listed |
| Codeine | Marketed | Phase 4 | none listed |
| Oxymorphone | Marketed | Phase 4 | Ends 2029 |
| Cebranopadol | Stopped | Phase 3 | none listed |
| AZD-7268 | Went quiet | Phase 2 | none listed |
| ADL-5859 | Went quiet | Phase 2 | none listed |
| Axomadol | Went quiet | Phase 2 | none listed |
| Adl-5747 free base | Stopped | Phase 2 | none listed |
| Ondelopran | Went quiet | Phase 3 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 7 |
| Engaged | 5 |
| Undetermined | 16 |
| Total on the list | 34 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Hikma Pharmaceuticals | Route B |
| Orexigen Therapeutics | Route B |
The other 31 companies at OPRD1
In the product34 companies in all; 31 are not named here, and no score is.
See the 34 companies at OPRD1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.